Trial results for a Phase 2 study evaluating atezolizumab in combination with bevacizumab and chemotherapy for EGFR-mutant non-small cell lung carcinoma (NSCLC) were posted on ClinicalTrials.gov on 2026-05-12. The study reported a median progression-free survival (PFS) of up to 7.6 months in one of the treatment arms.
Background
The study, known as ETOP 15-19 ABC-lung, investigated combinations of atezolizumab and bevacizumab with chemotherapy in patients with EGFR-mutant Stage IIIB/C or IV non-squamous non-small cell lung cancer (NSCLC). These patients had previously experienced failure of standard EGFR tyrosine kinase inhibitors (TKIs).
Trial design
The international, multi-centre, open-label, randomized Phase 2 trial (NCT04245085) enrolled 95 participants with EGFR-mutant Stage IIIB/C or IV non-squamous NSCLC after failure of standard EGFR TKIs. The study featured two non-comparative parallel arms: Arm A received atezolizumab plus bevacizumab with carboplatin-paclitaxel, while Arm B received atezolizumab, bevacizumab and pemetrexed.
Key results
Key results from the trial include:
- Median Progression-Free Survival (PFS): Arm A showed a median PFS of 6.4 months (95% Confidence Interval), while Arm B showed a median PFS of 7.6 months (95% Confidence Interval).
- Median Overall Survival (OS): Arm A had a median OS of 15.4 months (95% Confidence Interval), and Arm B had a median OS of 15.6 months (95% Confidence Interval).
- 12-month PFS Rate: In Arm A, 9 participants were progression-free at 12 months, corresponding to a rate of 20.9% (95% CI 10.0-36.0) with a p-value of 0.367. In Arm B, 11 participants were progression-free at 12 months, corresponding to a rate of 24.4% (95% CI 12.9-39.5) with a p-value of 0.174.
- Adverse Events: In Arm A, adverse events were reported for 43 participants, 1 participant, and 19 participants in distinct categories. In Arm B, adverse events were reported for 49 participants, 1 participant, and 23 participants in distinct categories.
What this means
This Phase 2 trial explored two distinct chemotherapy regimens in combination with atezolizumab and bevacizumab for patients with EGFR-mutant NSCLC who had progressed on EGFR TKIs. Arm B, which included pemetrexed, demonstrated a numerically longer median progression-free survival of 7.6 months and median overall survival of 15.6 months compared to Arm A (median PFS of 6.4 months and median OS of 15.4 months). However, the observed 12-month PFS rates of 20.9% for Arm A and 24.4% for Arm B did not meet the pre-specified efficacy threshold to reject the null hypothesis, indicating that the primary efficacy endpoint was not met for either arm. The adverse event counts suggest a generally comparable safety profile between the two arms, though specific details on severity or types of events are not provided in the posted results. These findings provide insights into potential combination strategies for this challenging patient population, despite not achieving the primary efficacy hypothesis.
Source
The information for these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT04245085, titled "ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma", were posted on 2026-05-12 on clinicaltrials.gov.